Privia Health vs Teladoc Health
PRVA and TDOC side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PRVA and TDOC compare
Privia Health is the larger company, worth 2.0 times as much as Teladoc Health ($3.1B against $1.6B).
Privia Health grew revenue faster over the last twelve months (19.2% versus −2.4% for Teladoc Health).
Privia Health keeps more of each dollar of sales as profit, with a net margin of 1.4% compared with −6.3% at Teladoc Health.
Privia Health scores higher on the StockData Score (16 against 4 for Teladoc Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PRVA | TDOC |
|---|---|---|
| Size and price | ||
| Market cap | $3.1B | $1.6B |
| Share price | $24.55 | $8.80 |
| Change, 1 year | 1.4% | 17.8% |
| Change, 5 years | −14.9% | −92.5% |
| Beta (5Y) | 0.66 | 1.97 |
| Employees | 1,226 | 5,600 |
| StockData Score | ||
| Total score | 16 (better) | 4 |
| Valuation score | 2 | 3 (better) |
| Growth score | 4 (better) | 0 |
| Performance score | 4 (better) | 1 |
| Health score | 6 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 94.4× | – |
| P/S | 1.3× | 0.6× (better) |
| P/B | 3.8× | 1.2× (better) |
| EV/EBITDA | 43.0× | – |
| P/FCF | – | 6.1× |
| FCF yield | – | 16.3% |
| Fair value | $15.32 | $13.40 |
| Margin of safety | −60.2% | 34.4% (better) |
| Growth | ||
| Revenue growth (TTM) | 19.2% (better) | −2.4% |
| Revenue growth, 5Y average | 21.0% (better) | 18.3% |
| Net income growth (TTM) | 91.3% | – |
| EPS growth (TTM) | 100% | – |
| EPS growth, 5Y average | −11.4% | – |
| Profitability | ||
| Gross margin | – | 68.6% |
| Operating margin | 2.1% (better) | −6.6% |
| Net margin | 1.4% (better) | −6.3% |
| FCF margin | – | 10.6% |
| Return on equity | 4.6% (better) | −11.5% |
| Return on invested capital | 10.0% (better) | −23.2% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −8.0× |
| Current ratio | 1.63 (better) | 0.87 |
| Altman Z-score | 4.60 (better) | −7.09 |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 96.7% | 83.6% |
| Held by insiders | 7.1% | 0.71% |
| Insider net buying, 12 months | −$22.2M | −$2.7M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 3.3% | 17.8% |
Go deeper
- PRVA stock overview
- PRVA income statement
- PRVA valuation and score
- TDOC stock overview
- TDOC income statement
- TDOC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.